. 2018 Jul 7;4(3):164–175. doi: 10.1016/j.cdtm.2018.04.002

Table 2.

Trials targeting PI3K/AKT/mTOR in breast cancer.

Study	Target	Treatment schedule	n	Results
BOLERO-2²⁰	mTOR	Everolimus plus exemestane vs. placebo plus exemestane	485 vs. 239	PFS: 11.0 vs. 4.1 months, HR = 0.38, P < 0.0001
BOLERO-3²¹	mTOR	Everolimus plus trastuzumab and vinorelbine vs. placebo plus trastuzumab and vinorelbine	284 vs. 285	PFS: 7.00 vs. 5.78 months, HR = 0.78, P = 0.0067
BELLE-3²²	PI3K	Buparlisib plus fulvestrant vs. placebo plus fulvestrant	289 vs. 143	PFS: 3.9 vs. 1.8 months, HR = 0.67, P = 0.0003
BELLE-2²³	PI3K	Buparlisib plus fulvestrant vs. placebo plus fulvestrant	576 vs. 571	PFS: 6.9 vs. 5.0 months, HR = 0.78, P = 0.00021
LOTUS²⁴	AKT	Ipatasertib plus paclitaxel vs. placebo plus paclitaxel	62 vs. 62	PFS: 6.2 vs. 4.9 months, HR = 0.60, P = 0.037

PI3K: phosphoinositide-3-kinase; AKT: v-akt murine thymoma viral oncogene homolog; mTOR: mechanistic target of rapamycin; PFS: progression-free survival; HR: hazard ratio; BOLERO-2: Initial Breast Cancer Trials of Oral Everolimus 2; BOLERO-3: Initial Breast Cancer Trials of Oral Everolimus 3.